A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Quotient Sciences.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-20 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Interventions
- Drug: AZD5462 film-coated tablet — also filed as AZD5462
- Drug: [14C]AZD5462 Solution for Infusion — also filed as AZD5462
- Drug: [14C]AZD5462 Oral Solution — also filed as AZD5462
Primary outcomes
what the primary-completion date above is the date OFAmount of AZD5462 excreted (Ae) - Period 1
measured Urine and faecal samples collected from pre-dose until 168 hours post-dose
Amount of AZD5462 excreted expressed as a percentage of the dose administered (Fe) - Period 1
measured Urine and faecal samples collected from pre-dose until 168 hours post-dose
Cumulative amount of AZD5462 excreted (CumAe) - Period 1
measured Urine and faecal samples collected from pre-dose until 168 hours post-dose
Cumulative amount of AZD5462 excreted expressed as a percentage of the dose administered (CumFe) - Period 1
measured Urine and faecal samples collected from pre-dose until 168 hours post-dose
Absolute bioavailability - Period 2
measured Plasma sample collection from pre-dose to 72 hours post-dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed